Transdermal Drug Delivery News

  1. Viatris Inc. Announces Receipt Of The First FDA Approval For Generic Version Of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide And Formoterol Fumarate Dihydrate Inhalation Aerosol), In Partnership With Kindeva 3/16/2022

    Viatris Inc. and Kindeva Drug Delivery announced that, Mylan Pharmaceuticals Inc., a Viatris subsidiary, has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for BreynaTM (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), the first approved generic version of AstraZeneca’s Symbicort®.

  2. Kindeva Drug Delivery To Manufacture New, Greener Inhalers At UK Manufacturing Site To Help Cut Carbon Emissions 2/16/2022

    One of the UK’s biggest asthma inhaler manufacturers has today announced its intention to invest in its UK manufacturing site to support the development of a new generation of greener inhalers, designed to help support the National Health Service (NHS) to cut a contributor to its emissions.

  3. Nutriband Inc. And Kindeva Drug Delivery Sign Feasibility Agreement To Develop AVERSA™ Fentanyl, An Abuse Deterrent Fentanyl Patch 1/10/2022

    The feasibility agreement is focused on adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA technology.